Search Results
Your search for ,VIA matches 1395 pages
Showing 1101 - 1150Johns Hopkins Kimmel Cancer Center Announces New Leadership Appointment
Michael A. Carducci, MD, Professor of Oncology and Urology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore was recently selected as Associate Director for Clinical Research. In this role, Dr. Carducci will facilitate clinical research activities as well as oversee...
Printed and Web-Based Decision Aids Improved Informed Decision-Making but Didn’t Alter Screening
Amid conflicting recommendations for prostate cancer screening and mixed messages communicated to the public about screening effectiveness, decision aids can assist men in making informed choices. A comparison of two different types of decision aids, one print-based and one Web-based, found that...
ASCO Challenges Its Members to Double Their Impact During the Month of September
For the entire month of September, donors to the Conquer Cancer Foundation of the American Society of Clinical Oncology have the opportunity to double their impact through a matching gift from an anonymous individual donor. From September 1 to 30, 2013, all donations—whether made online, through...
Sitimagene Ceradenovec/IV Ganciclovir in Glioblastoma: Legitimizing the Gene Therapy Approach for Brain Tumors
The ASPECT study,1 a randomized, open-label, phase III trial examining adenovirus-mediated gene therapy with sitimagene ceradenovec followed by IV ganciclovir for patients with operable high-grade glioma, is an important achievement for both neuro-oncology and gene therapy. As vector engineering...
Timely Findings From the Ovarian Tumor Tissue Analysis Consortium
In the Ovarian Tumor Tissue Analysis Consortium Study recently published by Sieh et al,1 tissue microarrays from 2,933 cases of epithelial ovarian carcinoma demonstrated that progesterone receptor (PR) expression and estrogen receptor (ER) expression were associated with significantly improved...
Pretreatment Lymph Node Dissection May Improve Survival in Advanced Cervical Cancer, But for Too Few?
Women with cervical cancer metastasized to para-aortic lymph nodes have historically had a poor prognosis, with 3-year overall survival rates of 25% to 40%.1-3 This has been attributed to the presence of occult systemic disease at the time of presentation and a high rate of distant recurrences...
A Great Privilege to Die Beneath an Open Sky
It was 1:00 AM, and my beeping pager awakened me. When you’re a surgical oncologist, you know that a page from your chief resident at this hour of the morning usually means someone may need to go to the operating room. And, yes, it was the chief resident about a patient in crisis. Except in this...
Paging Dr. Google: Practicing Oncology in the Era of Social Media and Telemedicine
Over the past few decades, economic and political factors have reshaped oncology, especially in the community setting. To defray risk, we’ve seen a trend toward oncology practices partnering with hospitals or aggregating into larger networks. Moreover, the Internet and the advent of telemedicine...
Fewer Weeks of Neoadjuvant Hormone Therapy Reduces Side Effects in Patients With Intermediate-Risk Prostate Cancer: RTOG 9910
A shorter course of androgen suppression therapy prior to radiation therapy, when compared to an extended course of androgen suppression therapy, yields comparable outcomes and fewer adverse effects for intermediate-risk prostate cancer patients, according to research presented recently at the 55th ...
Myeloma Foundation Launches Open Access Gateways to Accelerate Drug Development
The Multiple Myeloma Research Foundation (MMRF) has announced two open access gateways, the MMRF Researcher Gateway, which will upload genomic data as it becomes available and make it accessible to all researchers, and the MMRF CoMMunity Gateway, which will aggregate subtypes of myeloma patients...
Dr. Larry Norton, Honored at 2013 Breast Cancer Symposium, Calls For A Return to the 'Exploration of Concepts'
Larry Norton, MD, of Memorial Sloan-Kettering Cancer Center, is the recipient of the 2013 Gianni Bonadonna Breast Cancer Award, which he received at the 2013 Breast Cancer Symposium. The Symposium is sponsored by ASCO, the American Society of Breast Surgeons, the American Society of Radiation...
Trying to Improve Value in Cancer Care: An Experiment
One of the more significant problems in modern oncology practice is to provide increased value at a time when costs are spiraling upward, and new parameters of “success” are being introduced into the equation—most visibly, inside the Beltway in Washington, DC. Thus, oncologists will need to address ...
Association of Community Cancer Centers' 2013 Innovator Award Recipients Announced
Ten cancer programs that have developed pioneering solutions to address the challenges of treating cancer patients have received the Association of Community Cancer Centers’ (ACCC) 2013 Innovator Awards. Established in 2011, ACCC’s Innovator Awards are sponsored by GE Healthcare. The award...
Nab-Paclitaxel in Metastatic Pancreas Cancer
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication On September 6, paclitaxel protein-bound particles...
ASCO Teams Up with the GetWell Network to Provide More Patients With Education Resources
Through a new initiative and partnership with the GetWell Network, ASCO has begun to offer patient education content from its patient information website, Cancer.Net, to patients treated at hospitals within the GetWell Network community. The GetWell Network provides tools to hospitals to help...
Take-Home Messages From the NCCN Hematologic Malignancies Conference
As the National Comprehensive Cancer Network (NCCN) 8th Annual Congress: Hematologic Malignancies was drawing to a close, The ASCO Post spoke with Andrew D. Zelenetz, MD, PhD, about the themes of the meeting and the take-home messages for attendees and for our readers. Dr. Zelenetz is Vice Chair...
In International Study, Patients Prefer Subcutaneous Over Intravenous Trastuzumab for Breast Cancer
Subcutaneous trastuzumab (not available in the United States) has been shown to have noninferior efficacy and similar pharmacokinetic and safety profiles compared with intravenous trastuzumab (Herceptin) in patients with early-stage HER2-positive breast cancer. In the PrefHer trial reported in...
Multicenter Analysis of Outcomes of Lymphoma in Pregnancy
Lymphoma is the fourth most frequent cancer to occur in pregnant women. In a multicenter retrospective analysis reported in Journal of Clinical Oncology, Andrew M. Evens, DO, MSc, Chief of Hematology/Oncology at Tufts University Medical Center, Boston, and colleagues examined treatment,...
ASCO Resources for Transitioning to ICD-10
ASCO has developed resources to educate and assist oncology practices in transitioning to the Center for Medicare and Medicaid Services (CMS) 10th Edition of its International Classification of Diseases (ICD-10) coding system. Practices are encouraged to prepare for the transition before the...
Where Is Adjuvant Bisphosphonate Therapy Now?
The adjuvant use of bisphosphonates in breast cancer continues to yield seemingly contradictory data despite a sound biologic basis and smaller pilot studies suggesting that dampening bone turnover with bisphosphonates can lessen the bone reservoir of micrometastases.1,2 Early adjuvant trials with...
Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication On November 1, 2013, obinutuzumab (Gazyva) was approved...
Society for Integrative Oncology Is Helping to Advance Evidence-Based, Comprehensive Integrative Health Care
Heather Greenlee, ND, PhD, was named President of the Society for Integrative Oncology (SIO) at the organization’s 10th International Conference in October. Dr. Greenlee is Assistant Professor in the Department of Epidemiology at the Mailman School of Public Health at Columbia University in New...
The Best of SIO
The following four abstracts, which describe findings in three clinical studies and one basic science study, were singled out as the top abstracts at this year’s International Conference of the Society for Integrative Oncology. Self-Administered Acupressure Zick S, Wyatt G, Murphy S; et al: The...
National Cancer Policy Summit: Setting Priorities for the Next 3 Years
Welcome to the meeting we hold every 3 years to choose our next projects,” said John Mendelsohn, MD, Chair of the National Cancer Policy Forum and Director of the Khalifa Institute for Personalized Cancer Therapy at The University of Texas M.D. Anderson Cancer Center, Houston. “We have here a...
SIDEBAR: Shared Decisions: What Should We Expect?
There is growing interest by patients, policymakers, and clinicians in shared decision-making as a means to include patients in health decisions and translate patient evidence into clinical practice. Conceptually, sharing of information seems like a natural interplay between doctors and their...
Friends of Cancer Research Launches New Online Forum: Engaging Innovation
Friends of Cancer Research recently announced the launch of the online forum Engaging Innovation (www.focr.org/EngagingInnovation). With this site, the group will host leaders from regulation, research, drug development, treatment, and advocacy, encouraging them to share insights and innovations in ...
ASCO Resources for Transitioning to ICD-10
ASCO has developed resources to educate and assist oncology practices in transitioning to the 10th Edition of the Center for Medicare and Medicaid Services International Classification of Diseases (ICD-10) coding system. Practices are encouraged to prepare for the transition before the October 1,...
Corrections to Note
In the January 15, 2014, issue of The ASCO Post, three errors occurred. These errors have since been corrected and revised versions of the articles may be viewed online at ASCOPost.com or via the QR code here. The errors were as follows below. Trastuzumab Dosing In the article “HER2-Positive...
Cancer.Net Expands Its Social Media Presence With Launch of Blog
In an effort to continue to bring patients and those who care about and for them the most timely, comprehensive cancer information, ASCO’s patient education website, Cancer.Net, has added a new interactive resource—the Cancer.Net Blog (www.cancer.net/blog). “We decided that a blog made sense for...
Amplifying the Signal: Foundation Donor Takes His Advocacy Into the Twittersphere
Michael A. Thompson, MD, PhD, a Medical Oncologist for Aurora Cancer Care and the Medical Director of Early Cancer Research at Aurora Health Care in Wisconsin, has become something of an expert on the Conquer Cancer Foundation. It began in 2006, when he received a Conquer Cancer Foundation of ASCO...
Irinotecan Drug-Eluting Beads Improve Outcomes in Colorectal Cancer Patients With Liver Metastases
Irinotecan drug-eluting beads (DEBIRI) given simultaneously with FOLFOX (leucovorin, fluorouracil, oxaliplatin) and bevacizumab (Avastin) in patients with unresectable colorectal liver metastasis improved response rates, increased resectability, and prolonged hepatic progression–free survival in a...
The Author Replies
I read with interest the note from Jeff Boyd, PhD, Senior Vice-President for Molecular Medicine at Fox Chase Cancer Center, calling into question my recent commentary about the high costs of partly validated testing in the domain of molecular medicine. One of the oldest tricks in the book is to...
The Ketogenic Diet in Cancer Control
Ketogenic (or very-low-carbohydrate) diets have been employed since the 1920s as nonpharmacologic therapies for epilepsy and, in some instances, have obviated the need for medication for that disease. Since the 1960s, the ketogenic diet has become better known as a means of managing obesity. This...
Telemedicine: Efficiency in Cancer Screening and Outreach
As defined by the U.S. Health Resources and Services Administration teleheath is “the use of electronic information and telecommunications technologies to support long-distance clinical health care, patient and professional health-related education, public health, and health administration.” It has ...
Telephone Education and Counseling Effective in Programs Targeting Familial/Genetic Cancer Risk Screening
Two studies recently reported in the Journal of Clinical Oncology indicate that telephone-based education or counseling initiatives can be successful in educating individuals at familial or genetic risk of cancer and in inducing these at-risk individuals to undergo recommended screening. In the...
Ongoing Clinical Trials Actively Recruiting Adolescent and Young Adult Survivors of Childhood Cancer
ADOLESCENT AND YOUNG ADULT CHILDHOOD CANCER SURVIVORS Study Type: Randomized/interventional Study Title: A Randomized Web-Based Physical Activity Intervention in Adolescent Survivors of Childhood Cancer Study Sponsor and Collaborators: St. Jude Children’s Research Hospital Purpose: Five-year...
Lenalidomide Acts in Myeloma by Degrading Lymphoid Transcription Factors IKZF1 and IKZF3
The mechanism of action of lenalidomide (Revlimid) in multiple myeloma and other B-cell neoplasms remains largely uncharacterized. In a study reported in Science, Krönke and colleagues identified one of the effects of lenalidomide in this setting. Use of quantitative proteomics showed that...
Raj Mantena, RPh, Makes $1 Million Donation to Conquer Cancer Foundation to Help Build the Future of Cancer Care
It is a challenge faced time and time again by oncologists: how to achieve the best possible outcomes for patients while simultaneously controlling costs, providing care that is both high quality and high value. Raj Mantena, RPh, the first individual to donate $1 million dollars to the Conquer...
Enhance Your ASCO Annual Meeting Experience With Attendee Resources
At the end of the month, more than 25,000 oncology professionals from around the world will meet in Chicago for the 2014 ASCO Annual Meeting. Will you be joining this global community? As you’re beginning to consider what to pack for your trip, keep in mind that you have a host of electronic...
We Need Your Vote: History’s Top 5 Cancer Research Achievements
Throughout the year, we are celebrating not only ASCO’s 50th anniversary, but also the tremendous progress achieved against cancer in the last 50 years. Thanks to the dedication and contributions of patients and researchers, and our nation’s long-standing commitment to funding clinical research,...
High-Risk Uterine Cancers Found in BRCA1 Mutation Carriers Who Had Preventive Oophorectomy but Not Hysterectomy
Prophylactic surgery to remove the ovaries and fallopian tubes is advised for women who carry BRCA mutations to reduce the risk of breast and ovarian cancer. This procedure, referred to as risk-reducing salpingo-oophorectomy, typically does not require a hysterectomy. However, a new study presented ...
Collaborative Exchange: The Expanded Access Program and Uridine Triacetate
The panel discussed the various aspects of obtaining a drug such as uridine triacetate through the expanded access program. Ms. Vogel: The expanded access program allows companies to provide patients access to their medicines while the drugs are still in preapproval process, but it is strictly...
Questions Answered About Uridine Triacetate
Q. What is uridine triacetate? A. It is an investigational, orally active prodrug of uridine currently under development as an antidote to overexposure of fluorouracil (5-FU). Although not yet approved by the U.S. Food and Drug Administration, it has been shown to be effective in treating patients...
Collaborative Exchange: Indications and Dosing
Indications and Dosing of Methotrexate and 5-FU Dr. Campen: The interesting thing about methotrexate is that it has been used for such a long time. You would think there would be a specific dose that would be considered “high dose,” but high dose is actually quite variable. [Dosage] depends on the...
CE Activity Instructions
CE is available on May 1, 2014 and expires on May 1, 2015. A continuing education activity for physicians, physician assistants, nurse practitioners, nurses, pharmacists, and other allied health professionals specializing in the field of oncology. This activity is supported by an unrestricted...
Epigenetic Reprogramming of HOXC10 Results in Endocrine Resistance in Breast Cancer
Resistance to aromatase inhibitors is a major problem in treatment of estrogen receptor (ER)-positive breast cancer. In a study reported in Science Translational Medicine, Pathiraja and colleagues found pervasive DNA hyper- and hypomethylation and enrichment for promoter hypermethylation of...
Inactivation of E3 Ubiquitin Ligase Cbl-b Allows Natural Killer Cells to Control Metastases
New therapeutic approaches to blocking inhibitory pathways of the immune system have raised hopes that such treatments might thwart development of metastases. In a study in Nature, Paolino and colleagues have shown that genetic deletion of the E3 ubiquitin ligase Cbl-b (casitas B-lineage...
An Oncologic Surgeon Discusses the Pros and Cons of Pursuing a Business Degree
Is pursuing a Master of Business Administration (MBA) degree a good idea for ambitious surgical oncologists who want to advance their careers? The ASCO Post recently spoke with Martin J. Heslin, MD, MSHA, Chief, Section of Surgical Oncology, University of Alabama at Birmingham (UAB) Medical Center, ...
Maximizing the Benefits of Exercise in Patients With Cancer
Many nonpharmacologic therapies increase both physical and emotional strength during cancer treatment as well as throughout survivorship. These therapies include the mind-body practices of meditation, self-hypnosis, guided imagery, and breath awareness, touch therapies including massage and...
The Role of Psychosocial Supportive Services in Palliative Care
More than 2 decades ago, Deane L. Wolcott, MD, helped develop comprehensive patient-centered psycho-oncology care in cancer centers across the country. Today, many aspects of that patient-centered care, including psychiatric, dietary, pain management, cancer rehabilitation medicine, survivorship,...
